A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study
Filip Janku,S. George,Albiruni Ryan Abdul Razak,Michael S. Gordon,D. Brooks,D.G. Flynn,Michael Kaufman,J. Pitman,Bryan D. Smith,Neeta Somaiah,E. Gerstenberger,D. Westwood,Oliver Rosen +12 more
Journal ArticleDOI
Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export.
TL;DR: Selinexor is a selective inhibitor of nuclear export and is an active agent in various malignancies, such as diffuse large B-cell lymphoma and multiple myeloma.
Journal ArticleDOI
Extraosseous Pericardial Ewing's Sarcoma
Fathi Azribi,Albiruni Ryan Abdul Razak,Georgina Bough,Daniela Lee,David W. Rowe,Nick Bown,Petra Dildey,Stephen Clark,Ruth Plummer +8 more
Journal ArticleDOI
Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
Navid Hafez,Hatem Soliman,Siqing Fu,Karen A. Gelmon,Albiruni Ryan Abdul Razak,Pamela N. Munster,Ulka N. Vaishampayan,Shumei Kato,P. N. Lara,Elizabeth M. Swisher,Andrew B. Nixon,Abhijit A. Patel,Yu Shyr,S. Percy Ivy,Patricia LoRusso,Joseph Kim +15 more
TL;DR: Cediranib suppresses expression of BRCA1, BRCa2, and RAD51 and increases sensitivity of tumors to poly-...
Journal ArticleDOI
291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors
Fabrice Barlesi,Martijn P. Lolkema,Kristoffer Staal Rohrberg,Cinta Hierro,Aurélien Marabelle,Albiruni Ryan Abdul Razak,Luis Teixeira,Valentina Boni,Wilson H. Miller,Charu Aggarwal,Martin Stern,Olivera Cirovic,Barbara Romagnoli,Randolph Christen,Raksha Dodia,Kevin Smart,Bernhard Reis,Nicolas Staedler,Carl Watson,Neeltje Steeghs +19 more
TL;DR: Treatment with selicrelumab in combination with atezolizumab was well tolerated in patients with advanced solid tumors, however, efficacy of the combination in this unselected population was limited, when compared to monotherapy efficacy of atezoledzinumab.